Carvedilol (Coreg)

A carbazole and propanol derivative that acts as a non-cardioselective beta blocker and vasodilator. It has blocking activity for ALPHA 1 ADRENERGIC RECEPTORS and, at higher doses, may function as a blocker of CALCIUM CHANNELS; it also has antioxidant properties. Carvedilol is used in the treatment of HYPERTENSION; ANGINA PECTORIS; and HEART FAILURE. It can also reduce the risk of death following MYOCARDIAL INFARCTION.

Also Known As:

Coreg; BM 14190; BM-14190; Carvedilol Hydrochloride; Carvedilol, (+); Carvedilol, (+)-isomer; Carvedilol, (+-)-isomer; Carvedilol, (-); Carvedilol, (-)-isomer; Carvedilol, (R)-isomer; Carvedilol, (S)-isomer; Carvedilol, 14C-labeled; Coropres; Dilatrend; Eucardic; Kredex; Querto; 14C-labeled Carvedilol; BM14190; Carvedilol, 14C labeled; 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-

Networked: 2111 relevant articles (366 outcomes, 708 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Torp-Pedersen, Christian: 25 articles (01/2021 - 06/2002)
2.	Lukas, Mary Ann: 24 articles (01/2011 - 02/2003)
3.	Cleland, John G F: 21 articles (12/2018 - 06/2002)
4.	Metra, Marco: 18 articles (02/2010 - 02/2002)
5.	Swedberg, Karl: 16 articles (01/2015 - 06/2002)
6.	Komajda, Michel: 15 articles (01/2015 - 06/2002)
7.	Di Lenarda, Andrea: 14 articles (11/2007 - 06/2002)
8.	Remme, Willem J: 13 articles (11/2007 - 07/2003)
9.	Krum, Henry: 12 articles (08/2017 - 10/2002)
10.	Gilbert, Edward M: 12 articles (04/2015 - 05/2002)

Related Diseases

1.	Heart Failure 04/01/1996 - "The Australia and New Zealand carvedilol heart failure study is the largest completed study of beta-blocker treatment in patients with heart failure of ischaemic aetiology, including 415 patients randomized to carvedilol or placebo and indicating excellent tolerability of a titrated dose regimen and improved ventricular function after 6 months of treatment. " 03/01/2011 - "We hypothesized that carvedilol might be another safe treatment option in chronic AR, considering its combined β-blocking and α-blocking effects and proven efficacy in patients with established heart failure. " 10/16/2007 - "One drug, carvedilol, a nonsubtype-selective betaAR antagonist, has proven particularly effective in the treatment of heart failure, although the mechanism(s) responsible for this are controversial. " 09/01/2007 - "Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure." 12/01/2003 - "The total carvedilol dose was confirmed to be one of the determinants for improvement in heart failure, and it was suggested that the initial serum level also plays an important role in therapeutic outcome. "
2.	Hypertension (High Blood Pressure) 01/01/1994 - "This study showed that carvedilol is safe and effective in the treatment of mild to moderate hypertension and that there is a high prevalence (nearly 40%) of low ambulatory blood pressure means in a population labelled as mild to moderate hypertensive." 01/01/2011 - "It was concluded that there were no clinically significant issues in terms of safety or efficacy with the long-term treatment of carvedilol in patients with hypertension." 01/01/2012 - "Multiple-unit system exhibited enhanced bioavailability and sustained release of carvedilol, indicating its improved therapeutic potential for the treatment of hypertension." 03/01/2000 - "We thus selected carvedilol, a beta-blocker with slight alpha-blocking action, and were more effective in abolishing the hypertension." 01/01/1987 - "The present study also suggests that low-dose carvedilol once daily may be effective in the treatment of hypertension."
3.	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 01/01/2001 - "Carvedilol is well tolerated in infants with dilated cardiomyopathy and there is significant improvement in their functional status. " 08/01/2000 - "Notably, by the end of the first month of treatment, the antiarrhythmic efficacy of the drug was significantly greater in patients with ischaemic than in those with idiopathic dilated cardiomyopathy, an effect that could probably be attributed to the anti-ischaemic properties of carvedilol. " 08/01/2000 - "Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: double-blind, randomized, placebo-controlled study." 03/01/2000 - "Improvement in left ventricular function in response to carvedilol is accompanied by attenuation of neurohumoral activation in patients with dilated cardiomyopathy." 05/01/2019 - "The aim of this study was to evaluate the clinical efficacy of carvedilol on patients with dilated cardiomyopathy. "
4.	Cardiomyopathies (Cardiomyopathy) 12/01/2005 - "As it follows from our experience dilatrend is very effective for treatment of dilatative cardiomyopathy of alcoholic genesis." 01/01/1996 - "In ischemic cardiomyopathy, carvedilol appears to be effective to improve prognosis. " 03/01/2011 - "Carvedilol exerted protective effects against volume-overload cardiomyopathy in this model of aortic valve regurgitation with preserved ejection fraction. " 10/01/1997 - "In the US carvedilol studies (n = 1094), also in patients with ischaemic and idiopathic cardiomyopathy, carvedilol reduced mortality by 65%, which was highly significant. " 12/02/2016 - "In conclusion, high dose carvedilol triggered additional LVRR in patients with idiopathic non-ischemic cardiomyopathy and the change rates of log BNP, LVDd, and LVDs at 20 mg carvedilol may be predictors for the additional LVRR at high dose."
5.	Left Ventricular Dysfunction 12/01/2001 - "The purpose of this study was to assess the tolerability and efficacy of carvedilol in patients > 70 years with CHF associated with LV systolic dysfunction. " 04/01/2021 - "The grade of left ventricular diastolic dysfunction was improved at 3 months after the carvedilol treatment. " 08/01/2012 - "The present study investigated the possible protective role of carvedilol on ADR-induced left ventricular dysfunction in children with ALL. " 01/01/2011 - "We performed a post hoc analysis of pooled individual patient data (n=4217) from 2 multinational, double-blinded, placebo-controlled, randomized trials, CAPRICORN (Carvedilol Postinfarct Survival Control in Left Ventricular Dysfunction Study) and COPERNICUS (Carvedilol Prospective Randomized, Cumulative Survival study). " 01/01/2004 - "CARMEN is the first study to demonstrate that early combination of ACE-I and carvedilol reverses LV remodelling in patients with mild to moderate HF and LV systolic dysfunction. "

Related Drugs and Biologics

1.	Metoprolol (Toprol-XL)
2.	Propranolol (Inderal)
3.	Antioxidants
4.	Bisoprolol (Concor)
5.	Nebivolol
6.	Adrenergic Receptors (Adrenergic Receptor)
7.	Antihypertensive Agents (Antihypertensives)
8.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
9.	Atenolol (Tenormin)
10.	Diuretics

Related Therapies and Procedures

1.	Therapeutics
2.	Renal Dialysis (Hemodialysis)
3.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
4.	Drug Therapy (Chemotherapy)
5.	Ligation